Silarus Therapeutics is developing erythroferrone-targeting therapeutics for the treatment of iron disorders

September 22, 2014 – Silarus Therapeutics, Inc. was launched by Avalon Ventures in collaboration with GlaxoSmithKline (GSK). Silarus Therapeutics will receive up to $10 million in Series A financing and R&D support from Avalon Ventures and GSK. Silarus Therapeutics was founded based on intellectual property developed at the UCLA Center for Iron Disorders, related to the hormone erythroferrone that regulates the iron supply for red blood cell production.

Read more here